CHMP assessment report - European Medicines Agency€¦ · to risankizumab at entry of Part B in Study M16 -010 and received risankizumab in Study M15-997 . ... complete quality data,

  • Upload
    others

  • View
    0

  • Download
    0

Embed Size (px)